Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(7):426-427; doi:10.1093/jnci/djj116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Freemantle, S. J.
Right arrow Articles by Dmitrovsky, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freemantle, S. J.
Right arrow Articles by Dmitrovsky, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

The Retinoic Acid Paradox in Cancer Chemoprevention

Sarah J. Freemantle, Konstantin H. Dragnev, Ethan Dmitrovsky

Affiliations of authors: Departments of Pharmacology and Toxicology (SJF, ED) and Medicine (KHD, ED), Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH; Dartmouth-Hitchcock Medical Center, Lebanon, NH (SJF, KHD, ED)

Correspondence to: Sarah J. Freemantle, PhD, Remsen 7650, Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755 (e-mail: sarah.freemantle@dartmouth.edu).

The first 10% of the full text of this article appears below.

Decades of basic scientific studies and initial clinical trials have indicated a potential role for the classical retinoids in cancer chemoprevention (1). Indeed, the concept of clinical cancer chemoprevention is based largely on preclinical and early clinical studies in which retinoids suppressed epithelial carcinogenesis (2–5). However, in a recent randomized phase III intergroup chemoprevention trial, the retinoid isotretinoin did not reduce second primary tumor formation, recurrences, or mortality in patients with stage I non–small-cell lung cancer (6). And in this issue of the Journal, Khuri et al. (7) report results of a rigorously conducted placebo-controlled phase III trial showing that isotretinoin was not effective in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin
Perspectives for Cancer Prevention With Natural Compounds
J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
G. D. Stoner
Foodstuffs for Preventing Cancer: The Preclinical and Clinical Development of Berries
Cancer Prevention Research, March 1, 2009; 2(3): 187 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. H. Dragnev, W. J. Petty, S. J. Shah, L. D. Lewis, C. C. Black, V. Memoli, W. C. Nugent, T. Hermann, A. Negro-Vilar, J. R. Rigas, et al.
A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1794 - 1800.
[Abstract] [Full Text] [PDF]